Forman v. Novartis Pharmaceuticals Corp.
793 F. Supp. 2d 598
E.D.N.Y2011Background
- NPC seeks to bar punitive damages under New Jersey law; NJPLA NJPDA framework governs punitive damages in product liability actions; preemption and standing issues are central to the motion; the disputed exception to immunity under N.J.S.A. § 2A:58C-5(c) relates to fraud-on-the-FDA; the Court must decide whether federal law preempts the NJPLA exception and whether plaintiff has standing to pursue punitive damages; the Deutsch settlement occurred after the relevant pretrial proceedings and informs but does not bind Forman’s case
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Federal preemption of the NJPLA exception | Desiano/Garcia path supports non-preemption | McDarby controls preemption; Buckman framework applies | Preemption not established; FDCA does not preempt the exception |
| Standing to pursue punitive damages | Plaintiff asserts standing to prove fraud-on-the-FDA prerequisite | Standing to pursue punitive damages is challenged | Plaintiff has standing |
| Genuine issue of fact for punitive damages | Fraud-on-the-FDA prerequisite plus NJPDA factors show liability | Insufficient evidence to defeat summary judgment on punitive damages | Court declines to rule on this at this stage |
| Classification of NJSA § 2A:58C-5(c) under Desiano vs Buckman | NJPLA claim premised on traditional tort duties, not solely fraud-on-FDA | NJPLA exception is Buckman-like and preempts; FDA focus | Not preempted; Desiano-based analysis applied |
| FDCA preemption of fraud-on-the-FDA exception | Fraud-on-the-FDA is a prerequisite, not the sole basis | Buckman preemption would bar such claims | FDCA does not preempt the exception |
Key Cases Cited
- Buckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341 (2001) (fraud-on-the-FDA preemption limits such claims)
- Wyeth v. Levine, 555 U.S. 555 (2009) (presumption against preemption applies; state torts complement FDA regulation)
- Desiano v. Warner-Lambert & Co., 467 F.3d 85 (2d Cir.2007) (distinguishes fraud-on-the-FDA from traditional torts; preemption not per se)
- Garcia v. Wyeth-Ayerst Labs., 385 F.3d 961 (6th Cir.2004) (preemption of fraud-on-the-FDA-like claims under Michigan statute)
- McDarby v. Merck & Co., 401 N.J.Super. 10, 949 A.2d 223 (N.J.Super.App.Div.2008) (held federal preemption of NJPLA punitive-damages exception; Buckman-based analysis)
- Silkwood v. Kerr-McGee Corp., 464 U.S. 238 (1984) (punitive damages not preempted where based on traditional tort law)
- Chamber of Commerce of United States v. Whiting, U.S. , 131 S. Ct. 1968 (2011) (high threshold for implied preemption; limits judicial second-guessing of Congress)